-
2024-09-23
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia
Nuance Pharma announced that it has agreed with Altamira Medica Ltd. to extend the territory covered by the exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia.
-
2024-09-11
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
Nuance Pharma announced it has completed the recruitment of patients for the ENHANCE-CHINA study, after planned number of patients have been successfully enrolled.
-
2024-08-14
PharmaBoardroom Interview with Nuance Pharma founder & CEO Mark Lotter
From a demographic and disease profile perspective, Asia-Pacific shares more similarities with China than with Western markets. This alignment makes expanding into Asia-Pacific a logical step.
-
2024-06-27
US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patie
- 1
Contact PR
